Notably, recent research has underscored the clinical significance of cGAS-STING activation in NSCLC, revealing a correlation between enhanced expression of cGAS, CCL5, and CXCL10 and a favorable prognosis in patients with NSCLC undergoing chemotherapy and immunotherapy.29 The gene discussed is STING1; the disease is non-small cell lung carcinoma.